Trial Profile
Study to evaluate different treatment regimes of 40kD pegylated interferon alfa 2a (Pegasys) plus ribavirin on sustained virological responses (SVR) in genotype 3 HCV infected cirrhotic patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms STEPS
- 01 Jun 2012 Primary endpoint 'Sustained-virological-response-rate' has been met.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed.
- 12 Apr 2012 New source identified and integrated (EudraCT2007-002743-24: European Clinical Trials Database).